Aligos Therapeutics (ALGS) Net Margin (2021 - 2025)
Aligos Therapeutics (ALGS) has disclosed Net Margin for 5 consecutive years, with 11763.91% as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Net Margin fell 1483953.0% year-over-year to 11763.91%, compared with a TTM value of 1106.72% through Dec 2025, down 1573448.0%, and an annual FY2025 reading of 1106.72%, up 3817801.0% over the prior year.
- Net Margin was 11763.91% for Q4 2025 at Aligos Therapeutics, down from 4256.01% in the prior quarter.
- Across five years, Net Margin topped out at 13854.66% in Q1 2025 and bottomed at 101363.16% in Q3 2024.
- Average Net Margin over 5 years is 6826.12%, with a median of 1136.98% recorded in 2022.
- The sharpest move saw Net Margin crashed -10052560bps in 2024, then soared 9710715bps in 2025.
- Year by year, Net Margin stood at 10276.29% in 2021, then soared by 98bps to 157.37% in 2022, then tumbled by -364bps to 730.35% in 2023, then surged by 521bps to 3075.63% in 2024, then crashed by -482bps to 11763.91% in 2025.
- Business Quant data shows Net Margin for ALGS at 11763.91% in Q4 2025, 4256.01% in Q3 2025, and 1643.83% in Q2 2025.